1.15p
0.00%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cizzle Biotechnology Holdings
Its shares trade on LSE under the ticker CIZ.L. It has been listed since 23 May 2007. In the fiscal year to 31 December 2018, it reported revenue of £74,000 and a net loss of £2.1m. At that date it held total assets of £96,000 and shareholders' equity of −£235,000.
Cizzle Biotechnology Holdings Plc is a holding company, which engages in detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. The Company’s proof-of-concept prototype test is based on the ability to detect a plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. The company helps to reduce the need for repeated computed tomography (CT) scanning. The firm provides its product AZD1656 is treatment for COVID19 patients. AZD1656 is an immunomodulator which damps down the inflammatory response characteristic of coronavirus disease (COVID-19) infection, while enhancing the part of the immune response. The firm has developed a prototype confirmative test to address the false positive rates of CT scanning to avoid unnecessary invasive testing.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 May 2007
- Website
- cizzlebiotechnology.com ↗
Leadership
Pay as last reported
- Dr. Allan SymsExecutive Chairman of the Board, since 2019£93,000
- Mr. Nigel LeeFinance Director, Executive Director, since 2021£37,000
- Prof. Dawn CoverleyChief Scientific Officer, Executive Director, since 2021£41,000
- Mr. Matt BowerNon-Executive Director
- Mr. Edwin MatthewNon-Executive Director
- Mr. John TreacyNon-Executive Independent Director£30,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CIZ1B biomarker test reduces need for repeated CT scans in lung cancer detection.
- AZD1656 immunomodulator treats COVID-19 by dampening inflammatory response.
- Prototype confirmative test addresses false positives from CT scans avoiding invasive procedures.
Weaknesses
- Cizzle Biotechnology Holdings PLC listed on 23 May 2007 lacks detailed financial data.
- The company operates in London, GB, with limited market presence in Health Care sector.
- CIZ1B variant detection relies on plasma biomarker technology with unproven scalability.
Opportunities
- Expanding Health Care sector offers growth for lung cancer detection solutions.
- Global demand for effective COVID-19 treatments like AZD1656 increases market potential.
- Reducing false positives in CT scans can improve healthcare efficiency worldwide.
Threats
- Health Care sector competition intensifies with new biomarker detection technologies.
- Regulatory challenges may delay approval for CIZ1B test and AZD1656 treatment.
- Global health crises could shift focus from lung cancer to pandemic response priorities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.